Voyles v. SmithKline Beecham Corp.

524 F.3d 249, 390 U.S. App. D.C. 56, 2008 U.S. App. LEXIS 9625
CourtCourt of Appeals for the D.C. Circuit
DecidedApril 29, 2008
DocketNo. 07-5358
StatusPublished
Cited by1 cases

This text of 524 F.3d 249 (Voyles v. SmithKline Beecham Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Voyles v. SmithKline Beecham Corp., 524 F.3d 249, 390 U.S. App. D.C. 56, 2008 U.S. App. LEXIS 9625 (D.C. Cir. 2008).

Opinion

Opinion for the Court filed by Circuit Judge BROWN.

Circuit Judge HENDERSON concurs in the judgment.

BROWN, Circuit Judge.

GlaxoSmithKline (GSK) appeals a district court order quashing a subpoena commanding David Voyles, a Smithsonian employee, to testify at a deposition. GSK planned to ask him about his personal observations of a co-worker’s behavior. Because GSK’s request for information does not violate federal sovereign immunity, we reverse and remand to the district court for further proceedings.

I

Bobby Collins committed suicide and his family claims “Paxil,” an anxiety-disorder drug made by GSK, is to blame. The Collins family sued GSK in Pennsylvania state court, alleging Paxil radically changed Collins’ behavior and led him to take his own life. GSK asserts Paxil caused no such change. To help prove it, GSK wants to depose Voyles, Collins’ supervisor at the Smithsonian, about Collins’ behavior before he began taking Paxil. During an informal interview, Volyes told GSK that Collins didn’t get along well with his coworkers and his mood changed dramatically from one day to the next.

Through interviews with other employees, GSK learned Christine Nicholson, the Smithsonian’s Associate General Counsel, advised them not to speak with GSK without her approval. Believing GSK’s inquiries implicated federal sovereign immunity, Nicholson instructed Smithsonian employees not to comply with any state court subpoena. However, Nicholson allowed GSK to informally interview another Smithsonian employee in her presence, and she did not object to any of GSK’s questions. When GSK told her it would depose Voyles, Nicholson warned GSK that she would have the subpoena proceedings removed to federal district court and move to quash it.

Undeterred, GSK obtained a commission from the Pennsylvania court to depose Voyles. That court sent the commission to the Superior Court of the District of Columbia, which issued a subpoena on August 14, 2007 commanding Voyles to testify at a deposition two weeks later.

On August 24, the United States Attorney removed the proceedings to federal district court on Voyles’ behalf. The government moved to quash the subpoena, claming that Voyles’ observations were official Smithsonian information because Voyles only saw Collins at work; therefore, sovereign immunity barred the district court from enforcing the subpoena. Moreover, despite GSK’s repeated assurances that it would schedule the deposition at a time and place convenient to the Smithsonian, the government claimed practical reasons — the potential flood of importunate requests — also made the subpoena improper.

Without explanation, the district court granted the government’s motion to quash [58]*58on October 12, 2007 in a one-sentence minute order. GSK now appeals that order.1

II

The government claims sovereign immunity deprived the Superior Court of power to enforce the subpoena, and because the district court’s jurisdiction on removal was derivative, the district court properly quashed the subpoena. We assume this is why the district court quashed the subpoena. Since neither party disputes the underlying facts, we review de novo the issue of whether sovereign immunity applies. See Peninsula Asset Mgmt. (Cayman) Ltd. v. Hankook Tire Co., 476 F.3d 140, 143 (2d Cir.2007) (per curiam).

A

We first address whether removal was proper. Voyles is currently the Associate Director of Finance for the Smithsonian’s Office of Facilities, Engineering and Operations. At the time he observed Collins, he was the Chief of the Security Services Division for the Office of Protection Services. In relevant part, 28 U.S.C. § 1442(a)(1) permits “any officer ... of the United States or of any agency thereof,” or “any person acting under that officer,” to remove a “civil action” against “any act under color of such office.”

“[Ajgency” includes any “independent establishment ... of the United States ..., unless the context shows that such term was intended to be used in a more limited sense.” 28 U.S.C. § 451. Since the Smithsonian is an “independent establishment of the United States” within the Federal Tort Claims Act’s definition of “[federal agency,” Expeditions Unlimited Aquatic Enters., Inc. v. Smithsonian Inst., 566 F.2d 289, 296 (D.C.Cir.1977) (en banc opinion reinstating panel opinion), we conclude the Smithsonian is an “agency” of the United States under § 1442(a)(1).

Thus, as a “person acting under” an officer of the Smithsonian, Voyles may remove a “civil action” against his actions “under color of such office.” We have interpreted “civil action” as including state subpoena proceedings. Brown & Williamson Tobacco Corp. v. Williams, 62 F.3d 408, 413-14 (D.C.Cir.1995). An “act under color of such office” requires removal to “be predicated on the allegation of a colorable federal defense.” Id. at 413 (quoting Mesa v. California, 489 U.S. 121, 129, 109 S.Ct. 959, 103 L.Ed.2d 99 (1989)).

A state subpoena commanding a federal agency to produce its records or have its employees testify about information obtained in their official capacities violates federal sovereign' immunity. See Houston Bus. Journal, Inc. v. Office of the Comptroller of the Currency, 86 F.3d 1208, 1211 (D.C.Cir.1996). When a subpoena nominally directed at an agency employee seeks such information, courts nonetheless regard the subpoena as directed at the agency. See Boron Oil Co. v. Downie, 873 F.2d 67, 70-71 (4th Cir.1989); Sharon Lease Oil Co. v. FERC, 691 F.Supp. 381, 383-84 (D.D.C.1988). The employee may therefore remove the subpoena to district court and assert sovereign immunity as a defense. Just so here: Voyles claimed the subpoena requires him to testify “about facts [he] observed by virtue of his official duties and in his official capacity as a federal employee.” Notice of Removal of Subpoena 2, Aug. 24, 2007. Whether the subpoena will actually require Voyles to testify about such facts is a question we address next.

[59]*59B

Although we have decided the Smithsonian is an “independent establishment of the United States” within the FTCA’s definition of “[f]ederal agency,” we have never decided whether it is entitled to sovereign immunity. Forman v. Small, 271 F.3d 285, 295 (D.C.Cir.2001). But cf. Misra v. Smithsonian Astrophysical Observatory, 248 F.3d 37, 39 (1st Cir.2001) (“The Smithsonian is a federal agency which enjoys sovereign immunity from suit.”). In Expeditions Unlimited we expressly did “not reach the issue of the Institution’s immunity status at common law.” 566 F.2d at 296.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Subpoena in Collins
524 F.3d 249 (D.C. Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
524 F.3d 249, 390 U.S. App. D.C. 56, 2008 U.S. App. LEXIS 9625, Counsel Stack Legal Research, https://law.counselstack.com/opinion/voyles-v-smithkline-beecham-corp-cadc-2008.